Khona Scientific and Bright Path launch Project bioFORxGE

Bright Path and Khona Scientific have formed Project bioFORxGE to build a domestic, end-to-end manufacturing chain for essential medicines. The first demonstration will focus on paclitaxel and could extend to other taxane drugs as the companies aim to reduce supply chain bottlenecks.

Why it matters: - Project bioFORxGE is designed to strengthen U.S. production of generic and essential medicines. - The collaboration targets multiple supply chain weak points at once: KSM production, API synthesis, sterile manufacturing, and fill-finish capacity. - The first demonstration centers on paclitaxel, a widely used chemotherapy drug, because shortages can quickly affect patient care and public health. - The companies say the model could support broader reshoring of pharmaceutical manufacturing.

What happened: - Bright Path and Khona Scientific announced Project bioFORxGE on October 13, 2026, in Boulder, Colorado. - The project combines Khona Scientific’s biosynthesis platform with Bright Path’s chemisynthesis and drug product manufacturing capabilities. - The goal is a sovereign, end-to-end manufacturing platform for essential medicines. - Paclitaxel was selected as the lead API to demonstrate the integrated process.

The details: - Khona Scientific will use its BiDS™ platform to biosynthesize 10-deacetylbaccatin III, or 10-DAB, from renewable domestic sugar feedstocks. - 10-DAB is the KSM used to make all FDA-approved taxane APIs, including paclitaxel, docetaxel and cabazitaxel. - Bright Path will convert 10-DAB into paclitaxel API using its STT® reactor technology. - The collaboration also covers continuous-flow cGMP manufacturing and a sterile injectable paclitaxel drug product. - Paclitaxel is a taxane-based chemotherapeutic used for breast, ovarian and non-small cell lung cancers, as well as Kaposi sarcoma. - Paclitaxel is commonly used with platinum-based agents such as carboplatin and cis-platin. - The press release traces paclitaxel production from Pacific yew bark extraction to semi-synthesis from 10-DAB extracted from European yew needles. - The companies say ongoing shortages in sterile manufacturing and fill-finish capacity remain part of the bottleneck. - The stated milestones are an optimized biosynthetic route to 10-DAB, optimized continuous-flow cGMP manufacturing to paclitaxel API, and a manufacturing process for sterile injectable paclitaxel. - The same 10-DAB route could be used later for cabazitaxel and docetaxel APIs and drug products. - Bright Path describes its work as rebuilding America's pharmaceutical industrial base through domestic manufacturing. - Khona Scientific says its BiDS™ platform is built to produce complex natural-product compounds from renewable feedstocks.

Between the lines: - The partnership is meant to reduce dependence on fragmented global supply chains by linking raw feedstock, intermediate production, API synthesis and finished dosage manufacturing under one umbrella. - Paclitaxel is a practical test case because it sits at the intersection of therapeutic importance, supply vulnerability and manufacturing complexity. - If the process scales, the same framework could be applied to other taxane medicines. - The announcement frames pharmaceutical manufacturing resilience as both a healthcare issue and a national preparedness issue.

What's next: - The companies will work to demonstrate the optimized 10-DAB biosynthesis route. - They will also demonstrate continuous-flow cGMP conversion to paclitaxel API. - The final step is a sterile injectable paclitaxel drug product manufacturing process. - If successful, the platform may be repeated for docetaxel and cabazitaxel. - Bright Path and Khona Scientific say they will continue positioning the project as a domestic manufacturing model for essential medicines.

The bottom line: - Project bioFORxGE is an effort to build a U.S.-based, end-to-end taxane supply chain that could make critical cancer drugs less vulnerable to shortages. - More information is available in Khona Scientific's announcement and Bright Path's company site.